Moderna, Inc.

Moderna, Inc. is a pioneering biotechnology company based in Cambridge, Massachusetts, focused on the discovery, development and commercialization of messenger RNA (mRNA) therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases across the US, Europe, and the globe. Moderna’s mission is to combine the power of mRNA science with the potential of new technologies to create transformative medicines that address unmet medical needs and make a meaningful difference in peoples’ lives.

Moderna has a broad portfolio of respiratory vaccines, including COVID-19, the flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines, including cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines, such as Zika and Nipah vaccines. In addition, the company is developing systemic secreted and cell surface therapeutics, cancer vaccines (personalized cancer, KRAS, and checkpoint vaccines), intratumoral immuno-oncology products, localized regenerative therapies, systemic intracellular therapies and inhaled pulmonary therapeutics. In order to advance its pipeline and extend its reach, Moderna has established strategic alliances with some of the world’s leading biopharmaceutical companies, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, as well as collaborations and license agreements with Chiesi Farmaceutici S.P.A. and other organizations, such as Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation.

Moderna was founded in 2010, under the name Moderna Therapeutics, Inc., and in August 2018 changed its name to Moderna, Inc. In the past year, the company has made significant strides towards its mission. Moderna has raised over $6 billion for its mRNA vaccine program, made up of venture capital and corporate partnerships, and is currently in clinical trials for its COVID-19 vaccine. The company has also invested heavily in expanding its capability to manufacture its candidate therapeutics and vaccines; it now has three production facilities with the capacity to produce hundreds of millions of doses of its vaccines. Moderna has also made numerous strategic moves in order to expand its reach, including joining the main Nasdaq index in March 2020 and recently filing for the largest ever IPO for a biotechnology company. Moderna is now poised to enter the next phase of its growth and continue to make a meaningful difference in people’s lives.